Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Axsome Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -24.0%. For fiscal 2025 it was -26.1%, against -72.7% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -26.1% | +46.6 |
| FY2024 | Dec 31, 2024 | -72.7% | +12.9 |
| FY2023 | Dec 31, 2023 | -85.7% | +273.7 |
| FY2022 | Dec 31, 2022 | -359.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -22.7% | +1.7 |
| Q1 FY2026 | Mar 31, 2026 | -33.1% | +13.8 |
| Q4 FY2025 | Dec 31, 2025 | -13.8% | +47.4 |
| Q3 FY2025 | Sep 30, 2025 | -27.0% | +32.8 |
| Q2 FY2025 | Jun 30, 2025 | -24.5% | +65.1 |
| Q1 FY2025 | Mar 31, 2025 | -46.9% | +42.8 |
| Q4 FY2024 | Dec 31, 2024 | -61.1% | +76.2 |
| Q3 FY2024 | Sep 30, 2024 | -59.8% | +47.7 |
| Q2 FY2024 | Jun 30, 2024 | -89.5% | +49.8 |
| Q1 FY2024 | Mar 31, 2024 | -89.7% | −83.0 |
| Q4 FY2023 | Dec 31, 2023 | -137.4% | +108.5 |
| Q3 FY2023 | Sep 30, 2023 | -107.5% | +144.3 |
| Q2 FY2023 | Jun 30, 2023 | -139.3% | +304.9 |
| Q1 FY2023 | Mar 31, 2023 | -6.7% | – |
| Q4 FY2022 | Dec 31, 2022 | -245.9% | – |
| Q3 FY2022 | Sep 30, 2022 | -251.8% | – |
| Q2 FY2022 | Jun 30, 2022 | -444.2% | – |
See a number that looks wrong?